1. Scrip
  2. >>Therapy Areas

AstraZeneca Confident Of Cementing Lead In Respiratory

 
• By Kevin Grogan

The UK major’s head of respiratory and immunology, Pablo Panella, tells Scrip that AstraZeneca’s well established presence in the field “gives us an edge.”

Neon Light Sign Lungs Icon
• Source: Shutterstock

AstraZeneca PLC has been highlighting its role at the head of the biologics revolution taking place in the respiratory space and particularly chronic obstructive pulmonary disease (COPD) ahead of the American Thoracic Society (ATS) conference which kicks off in San Diego this weekend.

Pablo Panella, global head of respiratory and immunology at the UK major told Scrip that some four or five years ago, "we saw a retreat from innovation in the space and not a lot was happening but we were one of the few companies which stayed in and a lot of what is happening now is a result of that decision

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.